欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
本帖最后由 beiwei5du 于 2018-5-24 20:57 编辑
美国孤儿药法案30年(1983-2013),下面是2013年西雅图时报发表的两份报告,其中有涉及到药品利用孤儿药认定进行加快上市,并随后通过off-label use牟利的注册销售策略(主要在第二篇文章)。虽然该法案确实为推动罕见病治疗起到很大的作用,但是其也存在一定偏移Orphan Drug Act of 1983制定的初衷问题,成为制药企业牟利的工具。
Thirty years ago, Congress passed the Orphan Drug Act as a way to lure pharmaceutical companies to develop drugs for rare diseases that had been “orphaned” — abandoned or ignored because they were unprofitable. The hope was that drugmakers would break even or post modest profits.
The [pharmaceutical] industry has taken advantage of the incentives to charge excessive profits and to reap windfalls far in excess of their investments in the drug. — Henry Waxman, primary sponsor of the ODA
wiki:Orphan Drug Act of 1983(其中有两部电影"Seldom Silent, Never Heard" (1981) and "Give Me Your Weak" (1982)对于Orphan Drug Act的制定起到直接的推动作用)
Part 1: Mining of rare diseases | Pharma's Windfall | The Seattle Times
Part 2: Orphan drug earns millions | Pharma's Windfall | The Seattle Times
|